Drugs / ACT-1004-1239
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05549531 | Oct 2022 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04286750 | Jul → Sep 2020 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03869320 | Mar → Jul 2019 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACT-1004-1239 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05549531 ↗ |
| Action | Inhibit | “ACT-1004-1239 is a potent, selective, insurmountable, and orally available first-in-class CXCR7 receptor antagonist.” PMID 33595155 ↗ Mar 2021 |
| Route | Oral | “ACT-1004-1239 will be available for clinical study use as hard gelatin capsules for oral administration” NCT03869320 ↗ |
| Target | ACKR3 | “ACT-1004-1239 is a potent and selective, first-in-class ACKR3/CXRC7 antagonist” PMID 39010703 ↗ Jul 2024 |